Details of Disease

General Information of Disease (ID: DISKFYGZ)

Disease Name	Lassa fever
Synonyms	Lassa hemorrhagic fever; LF
Disease Class	1D61: Arenavirus disease
Definition	A viral hemorrhagic fever that is caused by the Lassa virus, which is transmitted by contact with infected rodents; it is characterized by fever, headache, malaise, myalgia, and hearing loss.
Disease Hierarchy	DISGFCIX: Vector-borne disease DISQEBTU: Viral hemorrhagic fever DISMA4RN: Arenavirus hemorrhagic fever DISHZ5WC: Lassa virus infectious disease DISKFYGZ: Lassa fever
ICD Code	ICD-11 ICD-11: 1D61.2
Disease Identifiers	MONDO ID MONDO_0005820 MESH ID D007835 UMLS CUI C0023092 MedGen ID 7276 Orphanet ID 99824 SNOMED CT ID 19065005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
INO-4500	DMLHPZG	Phase 1	Vaccine	[1]
LHF-535	DMFNSHM	Phase 1	Small molecular drug	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
DAG1	TT4X7PG	Limited	Biomarker	[3]
ATRAID	TTFLIKM	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
IFI30	OT9DERT1	Limited	Biomarker	[5]
SARS1	OTFKXQ1O	Limited	Biomarker	[5]
EEF1E1	OTRA6XOB	Strong	Biomarker	[4]
LAMTOR1	OTIBJBW9	Strong	Biomarker	[4]
MAFK	OTZJUE4P	Strong	Biomarker	[4]
TMBIM4	OT8712PP	Strong	Biomarker	[6]
TPPP2	OTI3WA6X	Strong	Biomarker	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DOT(s)

References

1	Clinical pipeline report, company report or official report of Inovio Pharmaceuticals.
2	ClinicalTrials.gov (NCT03993704) Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants. U.S. National Institutes of Health.
3	Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry.J Virol. 2012 Feb;86(4):2067-78. doi: 10.1128/JVI.06451-11. Epub 2011 Dec 7.
4	Characterization of virulence-associated determinants in the envelope glycoprotein of Pichinde virus.Virology. 2012 Nov 10;433(1):97-103. doi: 10.1016/j.virol.2012.07.009. Epub 2012 Aug 9.
5	GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus.Emerg Microbes Infect. 2019;8(1):1511-1523. doi: 10.1080/22221751.2019.1677446.
6	Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions.Med Microbiol Immunol. 2001 Sep;189(4):225-9. doi: 10.1007/s004300100061.